U.S. Insurance Stock News

BioCryst Pharmaceuticals (BCRX) recently issued full year 2026 earnings guidance, telling investors it expects total revenue between US$635 million and US$660 million, a data point that now anchors many discussions around the stock. See our latest analysis for BioCryst Pharmaceuticals. Even with the fresh 2026 revenue guidance and a slot at the J.P. Morgan Healthcare Conference, BioCryst Pharmaceuticals’ recent trading has been weak, with a 1 day share price return of 7.11% and a 7 day share...

In mid-January 2026, authID announced an integration with ServiceNow to bring secure, biometric identity verification into more than 8,400 ServiceNow-powered contact centers worldwide, including those used by most Fortune 500 companies, aiming to reduce fraud and strengthen audit trails for high-risk account changes and transactions. This move, coming alongside ServiceNow’s appointment of former Microsoft Chief Legal Officer Hossein Nowbar, underscores a broader push to reinforce trust,...

Earlier in January 2026, Littelfuse announced that Executive Vice President, Mergers & Acquisitions, Chief Legal Officer and Corporate Secretary Ryan K. Stafford will separate from the company effective April 30, 2026, while also preparing to release its fourth-quarter 2025 results on January 28, 2026. These leadership changes and upcoming earnings come as analysts highlight Littelfuse’s push into power semiconductors and EV charging infrastructure amid a broadly upbeat semiconductor...

If you are wondering whether Allstate's current share price lines up with its long term value, you are not alone. That is exactly what this article will unpack for you. After a strong multi year run, with returns of 64.1% over 3 years and 96.9% over 5 years, the stock has recently pulled back, with a 9.4% decline over 7 days, 8.0% over 30 days, and 5.7% year to date from a last close of US$192.28, while the 1 year return sits at 3.8%. Recent news flow around Allstate has focused on its...

In the past week, STERIS reported a quarterly update showing 9.9% year-on-year revenue growth, ahead of analyst expectations, alongside EBIT margin expansion to 23.1% and strong free cash flow generation. The results underscored the importance of STERIS’s recurring infection-prevention services and consumables, which, together with a sizeable healthcare capital backlog, enhanced visibility into future operating performance. Now we’ll consider how this margin expansion, driven by pricing and...

HA Sustainable Infrastructure Capital, Inc. and Sunrun Inc. recently closed a joint venture, under which HASI may invest up to US$500 million over 18 months to finance more than 300 megawatts of distributed home energy assets across over 40,000 installations nationwide. The structure allows HASI to monetize a portion of long-term customer cash flows while giving Sunrun enhanced flexibility in arranging senior project debt and retaining meaningful ownership. With this innovative joint venture...

Why Marqeta’s New CFO Matters for Investors Marqeta (MQ) has appointed Patti Kangwankij as Chief Financial Officer, effective February 9, 2026. This leadership change puts an experienced technology and payments executive at the center of its financial decision making. See our latest analysis for Marqeta. Despite the CFO appointment setting a fresh tone for execution, Marqeta’s recent 30 day share price return of 9.35% and year to date share price return of 3.88% are weaker, while the 1 year...

Why Willis Towers Watson (WTW) is on investors’ radar today Willis Towers Watson (WTW) has drawn attention after its recent share performance, with the stock last closing at US$329.41. Investors are weighing this pricing against the firm’s current earnings and growth profile. See our latest analysis for Willis Towers Watson. While the 1 day share price return of 0.28% is relatively small on its own, it sits alongside a year to date share price return of 0.96% and a 1 year total shareholder...

If you have been wondering whether Sprouts Farmers Market at around US$78.59 is still a fair deal or starting to look stretched, you are not alone. The stock has had a mixed run, with a 1.8% gain over the last 7 days, a 2.9% decline over the past month, a 2.5% decline year to date, a 43.6% return over the last year, a 151.9% return over 3 years, and a 267.1% return over 5 years. Recent coverage around Sprouts Farmers Market has focused on its positioning within the natural and organic...

Zimmer Biomet Holdings, Inc. recently disclosed that former executive officer Mark Bezjak will resign from the company and its affiliates on January 16, 2026, while CEO Ivan Tornos has outlined the company’s largest-ever direct-to-consumer campaign following multiple new orthopedic product launches. Together with management’s more cautious commentary at the J.P. Morgan Healthcare Conference, these moves highlight a period of management transition and recalibrated expectations as Zimmer...

AbCellera Biologics Inc. recently reported that it has begun dosing patients in the Phase 2 portion of its Phase 1/2 trial for ABCL635, a potential first-in-class non-hormonal treatment for moderate-to-severe menopausal vasomotor symptoms in 80 postmenopausal women. This marks the first clinical advancement from AbCellera’s GPCR and ion channel platform, highlighting how the company is moving its technology beyond discovery into internally owned therapies targeting menopause-related hot...

JetBlue Airways has recently expanded its Fort Lauderdale network with new year-round nonstop routes to Orlando and Dallas, added more daily flights to New York’s LaGuardia, and continued building out its Florida footprint with additional destinations and premium Mint offerings. This push deepens JetBlue’s role as Fort Lauderdale’s largest carrier and tightens connectivity across Florida and beyond, aligning its network more closely with leisure and visiting-friends-and-relatives travel...

BlackRock (BLK) has wrapped up FY 2025 with fourth quarter revenue of US$7.0b and basic EPS of US$7.26, while trailing 12 month figures show revenue of US$24.2b and EPS of US$35.83. Over recent periods, revenue has moved from US$20.4b in the trailing 12 months to Q4 2024 to US$24.2b by Q4 2025, with basic EPS shifting from US$42.45 to US$35.83 over the same comparison window. With trailing net profit margin at 22.9%, down from 31.2% a year earlier, the latest results pair solid top line...

Why Box Is On Investors’ Radar Today Box (BOX) is drawing attention after a period of weaker share performance, with the stock showing negative returns over the past month, past 3 months, and year, prompting investors to reassess its current valuation. See our latest analysis for Box. Box’s recent 1 day share price return of a 2.71% decline and 7 day share price return of a 12.99% decline come on top of weaker year to date share price performance. The 5 year total shareholder return of 44.74%...

Earlier this month, JPMorgan upgraded Calix to "Overweight," highlighting a healthier spending backdrop for broadband providers and the company’s exposure to US federal broadband deployment programs aimed at unserved and underserved areas. JPMorgan also pointed to Calix’s upcoming fourth-quarter earnings release and investor day as potential turning points that could further clarify how it may benefit from broadband stimulus funding. Now, we'll examine how JPMorgan's emphasis on Calix's...

What Sila Realty Trust’s latest acquisition could mean for investors Sila Realty Trust (SILA) has agreed to acquire a US$43.1 million inpatient rehabilitation facility in Oklahoma City, a 58 bed property that is fully leased under a long term absolute net lease. The Nobis OKC Facility, recently expanded by 18 beds and about 9,100 square feet to roughly 53,100 square feet, fits the company’s focus on healthcare real estate and may interest investors watching income oriented REITs. See our...

T. Rowe Price recently launched Income Solver through its fintech subsidiary Retiree Inc., offering advisors software to design personalized, tax-aware retirement withdrawal strategies that coordinate investment assets, Social Security, Medicare premiums, and other income sources. The tool is built on proprietary research that the company says can significantly extend retirement income while reducing manual planning work for advisors, underscoring T. Rowe Price’s focus on higher-value...

Pomerantz LLP is investigating Cogent Communications Holdings over potential securities law violations after the company previously reported a nearly 6% year-over-year service revenue decline and a 98% dividend reduction in November 2025. This combination of legal scrutiny and sharp cuts to shareholder payouts highlights growing concerns about Cogent’s financial flexibility and business resilience. We’ll now examine how the securities investigation and sharp dividend reduction may affect...

Earlier this month, Chinese authorities instructed domestic firms to stop using certain foreign cybersecurity software, including Broadcom-owned VMware products, citing national security concerns and adding fresh pressure to U.S. tech suppliers in the country. At the same time, Broadcom moved ahead with its AI-focused Wi‑Fi 8 platform and a US$4.50 billion senior notes issuance, underscoring how regulatory headwinds in China are emerging just as the company deepens its push into AI...

Wondering whether QXO at around US$23.81 is offering fair value or an opportunity? This article walks through what the current price actually reflects. The stock has been volatile recently, with a 4.8% decline over the last 7 days, a 14.5% gain over 30 days, a 20.7% return year to date, and a 70.2% return over the past year. The 3 year and 5 year returns sit at 11.6% and a 13.6% decline respectively. Recent coverage has focused on QXO as a name that has drawn attention following its share...

Organon’s Nilemdo deal and recent share move Organon (OGN) has signed an agreement with Daiichi Sankyo Europe to commercialize Nilemdo, a cholesterol lowering drug, across several European countries, extending its reach into treatments for high cardiovascular risk patients. This new commercial deal comes shortly after Organon’s stock gained about 21% over the past month. The move has drawn more attention to how its expanding cardiovascular portfolio might interact with upcoming earnings...

If you are wondering whether Somnigroup International at around US$94 is priced for perfection or still offers value, this breakdown will help you frame that question clearly. The share price comes with a 0.2% return over the last 7 days, 5.6% over 30 days, 5.9% year to date and 59.0% over the past year, with a 3 year return of 152.1% and 5 year return of 243.0% that many investors will want to put into context. Recent coverage has focused on Somnigroup International's position within its...

If you are wondering whether JPMorgan Chase at around US$312 per share is still good value or starting to look expensive, you are not alone. The stock has had a mixed run recently, with a 5.1% decline over the last 7 days and a 0.8% decline over the last 30 days, yet it shows a 23.0% return over 1 year and a very large 3 year and 5 year return of 148.4% and 165.2% respectively. Recent news around JPMorgan Chase has focused on its position as one of the largest global banks and its influence...

Recent share performance and business snapshot Tandem Diabetes Care (TNDM) has been under pressure recently, with the stock showing a 4.3% decline over the past day, 7.1% over the past week, and 10.1% over the past month, while gaining 36.3% over the past 3 months. The company reported revenue of US$1,007.001m and a net loss of US$203.366m, with annual revenue growth of 8.3% and annual net income growth that is very large. Its value score of 4 may interest investors who are comparing diabetes...